+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Myelofibrosis (MF) Pipeline Analysis 2019 (H1)

  • ID: 4801762
  • Report
  • May 2019
  • Region: Global
  • 79 pages
  • Knowledge Sourcing Intelligence LLP
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie
  • Acceleron Pharma, Inc.
  • Astra Zeneca
  • Bristol Myers Squibb
  • Celgene Corp
  • Celgene Corp
  • MORE
Myelofibrosis Pipeline Analysis report 2019 (H1) covers more than 10 drugs currently in different phases of development. Myelofibrosis is a chronic serious disorder which disrupts the normal production of the blood cells due to the excessive scarring in the bone marrow and belongs to a group of diseases called myeloproliferative disorders. The exact cause of the disease is yet not known however, some mutations affecting proteins that work in signaling pathways in the cells may be considered as the reason. Common symptoms of myelofibrosis are splenomegaly, fatigue, paler mucous membranes, and cachexia. Diagnoses are done by blood tests, bone marrow biopsy, and imaging tests.

The report provides Myelofibrosis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.

Major industry players profiled as part of the report are AbbVie, CTI BioPharma Corp., NS Pharma,Inc, and Bristol Myers Squibb among others.

Scope:
  • By Company
  • By Phase
  • By Molecule Type
  • By Region
  • By Route of Administration
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie
  • Acceleron Pharma, Inc.
  • Astra Zeneca
  • Bristol Myers Squibb
  • Celgene Corp
  • Celgene Corp
  • MORE
1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region

2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology

3. Executive Summary

4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities

5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
  • Drug Name
  • Generic Name
  • Synonyms
  • Company
  • Collaborator
  • Route of administration
  • Target
  • Mechanism of Action
  • Technology
  • Molecule type
  • CAS Number
  • Weight
  • Chemical Formula
  • IUPAC name
  • ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region

6. Company profiling
6.1. AbbVie
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.1.5. Recent Development
6.2. Constellation Pharmaceuticals
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.2.5. Recent Development
6.3. CTI BioPharma Corp.
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.3.5. Recent Development
6.4. Celgene Corp
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.4.5. Recent Development
6.5. Acceleron Pharma, Inc.
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.5.5. Recent Development
6.6. Celgene Corp
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.6.5. Recent Development
6.7. NS Pharma,Inc
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.7.5. Recent Development
6.8. Astra Zeneca
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.8.5. Recent Development
6.9. Bristol Myers Squibb
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.9.5. Recent Development
6.10. Stemline Therapeutics
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.10.5. Recent Development
6.11. Kartos Therapeutics
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.11.5. Recent Development
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie
  • Constellation Pharmaceuticals
  • CTI BioPharma Corp.
  • Celgene Corp
  • Acceleron Pharma, Inc.
  • Celgene Corp
  • NS Pharma,Inc
  • Astra Zeneca
  • Bristol Myers Squibb
  • Stemline Therapeutics
  • Kartos Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll